SPAG9

Across TCGA pan-cancer cohorts, SPAG9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPAG9 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPAG9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPAG9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where SPAG9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.982	0.891	.007	25	view →
LUAD	OS	Median	All	1.000	0.773	.006	13	view →
CCRCC	DFS	Median	IV	0.781	0.220	.017	10	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
LSCC	OS	Tertile	All	0.805	0.961	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPAG9–HNSC (DFS)

Open the HNSC breakdown →